Conference - Mumbai, India
The past decade has witnessed significant consolidation in the generic industry mostly because of patent expiry of large number of pharmaceutical innovator products. Given the tremendous pressure on both innovator and generic companies to maintain growth, this trend is likely to continue. This growth has also brought in stern competition amongst generic pharmaceutical companies in order to get a slice of pie out of the market. Innovation strategies, niche generics, cost reduction and reducing regulatory uncertainties are some of the topics to be deliberated for the success of generic pharmaceutical industry. The Generics track of this event aim to bring together the experience of Pharmaceutical Industry professionals for achieving this objective.
Quality and structure of biologics is of utmost importance because of their dependency on extremely narrow specifications in manufacturing processes. This track on Biologics will focus on development of quality biologics on one hand and regulatory requirements and compliance issues as well as expedited approval and market introduction of biosimilar competitors on the other hand. Biosimilars or follow-on-biologics or subsequent entry biologics provide potential cost saving opportunities for drug manufacturers and therefore will be in the spotlight.
Organization: SELECTBIO
(Courtesy of Generics & Biologics 2014 logo, via ddw-online.com)
Mon, Feb 24, 2014 - Tue, Feb 25, 2014
Ramada Powai Hotel & Convention Centre
Mumbai 400 087
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
